Ziftomenib and Encorafenib: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Encorafenib
Ziftomenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
An increased risk of QT interval prolongation, reduced ziftomenib exposure and reduced efficacy of ziftomenib
Interaction Deep Dive
Avoid concomitant use of ziftomenib with a strong or moderate CYP3A4 inducer with a known potential to prolong the QTc interval as it may reduce quizartinib exposure, which may reduce the efficacy of ziftomenib and may cause additive QT effects. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt ziftomenib if the QTc interval is more than 500 ms or the change from baseline is more than 60 ms. Concomitant use may also result in adverse reactions associated with QTc interval prolongation, including torsades de pointes, other serious arrhythmias, and sudden death. In drug interaction studies, coadministration of rifAMPin (strong CYP3A4 inducer) with ziftomenib is estimated to decrease ziftomenib AUC by up to 80% and Cmax by up to 70%. And, coadministration of efavirenz (moderate CYP3A4 inducer) with ziftomenib is estimated to decrease ziftomenib AUC and Cmax by up to 70%1.
Why it happens (mechanism)
Additive QT interval prolongation; induction of CYP3A4-mediated metabolism of ziftomenib
Literature reports
1 report — tap to read
a) In drug interaction studies, coadministration of rifAMPin (strong CYP3A4 inducer) with ziftomenib is estimated to decrease ziftomenib AUC by up to 80% and Cmax by up to 70%. And, coadministration of efavirenz (moderate CYP3A4 inducer) with ziftomenib is estimated to decrease ziftomenib AUC and Cmax by up to 70% 1.
Common questions
Can I take Ziftomenib and Encorafenib together?
An increased risk of QT interval prolongation, reduced ziftomenib exposure and reduced efficacy of ziftomenib Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ziftomenib and Encorafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Ziftomenib or Encorafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: KOMZIFTI™ oral capsules, ziftomenib oral capsules. Kura Oncology, Inc (per manufacturer), San Diego, CA, 2025. DailyMed
Keep reading about Encorafenib
Keep reading about Ziftomenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist